We are live on
!
Find out more
VCIM
Velan Capital Investment Management Portfolio holdings
AUM
$160M
1-Year Est. Return
517.12%
This Fund
S&P 500
This Quarter
Est. Return
+117.44%
1 Year Est. Return
+517.12%
3 Year Est. Return
+2,524.89%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$172M
AUM Growth
+$65.9M
(+62%)
Cap. Flow
+$15.6M
Cap. Flow
% of AUM
9.03%
Top 10 Holdings %
Top 10 Hldgs %
70.98%
Holding
57
New
8
Increased
5
Reduced
5
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
EVMN
Evommune Inc
EVMN
|
+$9.52M |
| 2 |
MPLT
MapLight Therapeutics
MPLT
|
+$8.75M |
| 3 |
ESPR
Esperion Therapeutics
ESPR
|
+$3.91M |
| 4 |
Protara Therapeutics
TARA
|
+$3.87M |
| 5 |
Verrica Pharmaceuticals
VRCA
|
+$2.61M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Praxis Precision Medicines
PRAX
|
+$5.96M |
| 2 |
ZOOZ
ZOOZ Strategy Ltd
ZOOZ
|
+$4.28M |
| 3 |
ALMS
Alumis Inc
ALMS
|
+$3.78M |
| 4 |
uniQure
QURE
|
+$1.87M |
| 5 |
TELA Bio
TELA
|
+$1.11M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.72% |
| 2 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Praxis Precision Medicines
PRAX
$10.2B
| $29.7M | 17.23% |
100,781
-32,024
| -24% | -$5.96M |
|
|
CDTX
2
DELISTED
Cidara Therapeutics
CDTX
| $23.9M | 13.89% |
108,404
| – | – |
|
|
3
Protara Therapeutics
TARA
$229M
| $15.1M | 8.76% |
2,834,652
+695,652
| +33% | +$3.87M |
|
4
Heron Therapeutics
HRTX
$69.5M
| $11.4M | 6.6% |
8,753,290
| – | – |
|
|
MPLT
5
MapLight Therapeutics
MPLT
$557M
| $9.17M | 5.32% |
+522,305
| New | +$8.75M |
|
|
ABVX
6
Abivax
ABVX
$11.2B
| $9.04M | 5.24% |
67,000
+2,611
| +4% | +$285K |
|
|
EVMN
7
Evommune Inc
EVMN
$510M
| $8.68M | 5.03% |
+506,754
| New | +$9.52M |
|
8
Mineralys Therapeutics
MLYS
$2.39B
| $5.48M | 3.18% |
151,000
-24,600
| -14% | -$987K |
|
9
Lantheus
LNTH
$6.59B
| $4.97M | 2.88% |
74,687
+1,142
| +2% | +$66.5K |
|
10
Jasper Therapeutics
JSPR
$26.4M
| $4.88M | 2.83% |
2,668,395
| – | – |
|
11
Avalo Therapeutics
AVTX
$1.04B
| $4.79M | 2.78% |
263,642
| – | – |
|
|
ESPR
12
DELISTED
Esperion Therapeutics
ESPR
| $4.48M | 2.6% |
+1,210,000
| New | +$3.91M |
|
|
13
Verrica Pharmaceuticals
VRCA
$91.7M
| $3.92M | 2.27% |
+471,559
| New | +$2.61M |
|
14
InspireMD
NSPR
$37.5M
| $3.82M | 2.21% |
2,143,698
| – | – |
|
|
RAPT
15
DELISTED
RAPT Therapeutics
RAPT
| $3.66M | 2.12% |
108,000
+28,023
| +35% | +$870K |
|
16
Sutro Biopharma
STRO
$423M
| $3.61M | 2.09% |
312,000
| – | – |
|
|
TERN
17
DELISTED
Terns Pharmaceuticals
TERN
| $2.83M | 1.64% |
70,000
+50,000
| +250% | +$1.16M |
|
18
Syndax Pharmaceuticals
SNDX
$1.82B
| $2.73M | 1.58% |
130,000
| – | – |
|
19
Viridian Therapeutics
VRDN
$2.58B
| $2.69M | 1.56% |
86,500
| – | – |
|
|
EPRX
20
Eupraxia Pharmaceuticals
EPRX
$440M
| $2.66M | 1.54% |
352,000
| – | – |
|
21
Trevi Therapeutics
TRVI
$2.56B
| $2.57M | 1.49% |
205,000
| – | – |
|
|
PROF
22
Profound Medical
PROF
$266M
| $2.25M | 1.3% |
+285,710
| New | +$1.84M |
|
|
KZIA
23
Kazia Therapeutics
KZIA
$159M
| $2.07M | 1.2% |
+300,000
| New | +$2.56M |
|
24
Rezolute
RZLT
$453M
| $1.77M | 1.03% |
750,000
| – | – |
|
25
Tenax Therapeutics
TENX
$51.3M
| $1.02M | 0.59% |
83,333
| – | – |
|
Similar funds
BFAG
SLG
SMF
LCA
SA
SGCM
CF
RP
Velan Capital Investment Management's Q4 2025 Portfolio in Review
As of Q4 2025, Velan Capital Investment Management held 57 positions worth $172M, up 62% from $106M the previous quarter. Its ten largest holdings account for 71% of the portfolio.
Velan Capital Investment Management deployed $15.6M of net new capital in Q4 2025, opening 8 new positions and adding to 5 existing holdings. Its largest new stake was Evommune Inc: 506,754 shares worth $8.68M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 96% a quarter earlier, followed by Industrials.
On the sell side, the largest reduction was Praxis Precision Medicines, an estimated $5.96M trimmed.
- Velan Capital Investment Management's largest Q4 2025 buy was Evommune Inc: 506,754 shares worth $8.68M.
- Velan Capital Investment Management added most to Protara Therapeutics in Q4 2025, an estimated $3.87M increase.
- Velan Capital Investment Management's biggest Q4 2025 reduction was Praxis Precision Medicines, cutting an estimated $5.96M.
- Velan Capital Investment Management fully exited ZOOZ Strategy Ltd in Q4 2025, selling an estimated $4.28M.
- Velan Capital Investment Management's ten largest holdings make up 71% of its $172M portfolio in Q4 2025.
- Velan Capital Investment Management opened 8 new positions and closed 11 in Q4 2025.
- Velan Capital Investment Management's portfolio value rose 62% quarter-over-quarter to $172M.
Based on Velan Capital Investment Management's 13F filing for Q4 2025, filed 13 Feb 2026.